

Anticipated date to be presented at LSCMMG	Guidance title	Specialty area	Type of guidance	Provider(s)	Capacity impact	Potential resource impact areas (costs or savings)	Financial risk level (see below for definition)	Additional information
Jul-24	Azithromycin PIL – update	Respiratory	Prescriber information sheet	Primary and secondary care	TBC	TBC	1	
Jul-24	Sodium zirconium cyclosilicate PIL – update	Renal	Prescriber information sheet	Primary and secondary care	TBC	TBC	1	
Jul-24	Items that Should not be Routinely Prescribed in Primary Care Policy – update	-	Guideline	Primary care	TBC	TBC	TBC	
Jul-24	Lancashire and South Cumbria Self-Care and Access to OTC Medicines	-	Guideline	Primary care	TBC	TBC	TBC	
Jul-24	Gastroenterology biologics pathway	Gastroenterology	Clinical guideline	Secondary care	TBC	TBC	TBC	
Jul-24	Psoriasis guideline - update	Dermatology	Clinical guideline	Secondary care	TBC	TBC	TBC	
Jul-24	Psoriatic arthritis guidance - update	Rheumatology	Clinical guideline	Secondary care	TBC	TBC	TBC	
Jul-24	Asthma treatment guidelines for children	Respiratory	Clinical guideline	Primary and secondary care	TBC	TBC	TBC	
Sep-24	Prescribing policy for specialist infant formula feeds – update	Nutrition	Clinical guideline	Primary care	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
Sep-24	Benzodiazepine withdrawal guidance	CNS	Clinical guideline	Primary care	TBC	TBC	1	Scope and format agreed by LSCMMG.
On-hold	Domperidone shared care consultation – UHMB paediatric shared care	Gastroenterology	Clinical guideline	Primary and secondary	TBC	£0.00	Cost neutral	To consider pausing to release capacity to prioritise formulary work.

On-hold	Enoxaparin shared care - UHMB	Cardiovascular	Clinical guideline	Primary and secondary	TBC	£0.00	Cost neutral	To consider pausing to release capacity to prioritise formulary work.
On-hold	Testosterone shared care - consider Amber 0 - consultation	Endocrine	Clinical guideline	Primary and secondary	TBC	£0.00	Cost neutral	To consider pausing to release capacity to prioritise formulary work.
On-hold	Cyanocobalamin guideline	Nutrition	Clinical guideline	Primary and secondary	TBC	TBC	TBC	To consider pausing to release capacity to prioritise formulary work.
TBC	Heart failure in diabetes guidance	Cardiovascular	Clinical guideline	Primary and secondary	TBC	TBC	TBC	TBC
TBC	Good prescribing in primary care guidance	Policy	Guideline	Primary care	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice

Financial risk level	1	2	3
	Threshold additional cost per patient per year/course Based on estimated (or actual) cost of the medicine per patient using usual maintenance dose for expected duration of treatment versus its comparator(s)	Threshold additional cost per likely population per year/course¹ Based on likely patient uptake, expected cost of the medicine, and reduced use of comparator(s)	Threshold additional cost per 100,000 people per year/course¹ Based on likely patient uptake, expected cost of the medicine, and reduced use of comparator(s)
Cost saving	Cost saving <£0	Cost saving <£0	Cost saving <£0
Cost neutral	£1 to <£700	£1 to <£1 million	£1 to <£2,000
Low	£700 to <£10,000	£1 million to <£15 million	£2,000 to <£30,000
High	≥£10,000	≥£15 million	≥£30,000